← Back to Screener
Axogen, Inc. Common Stock (AXGN)
Price$42.80
Value ScoreF
Growth ScoreB
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)41.46%
Price vs S&P 500 (4W)1.77%
VGM Score60.17
Market Capitalization$2.28B
All Metrics
P/CF (Annual)2802.97x
Book Value / Share (Quarterly)$4.61
P/TBV (Annual)12.36x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)17.56%
Cash Flow / Share (Quarterly)$0.14
Price vs S&P 500 (YTD)22.61%
Gross Margin (TTM)75.01%
Net Profit Margin (TTM)-13.21%
EPS (TTM)$-0.64
10-Day Avg Trading Volume0.77M
EPS Excl Extra (TTM)$-0.64
Revenue Growth (5Y)14.93%
EPS (Annual)$-0.34
ROI (Annual)-8.86%
Gross Margin (Annual)74.31%
Net Profit Margin (5Y Avg)-13.60%
Cash / Share (Quarterly)$1.91
Revenue Growth QoQ (YoY)26.56%
ROA (Last FY)-7.08%
Revenue Growth TTM (YoY)22.41%
EBITD / Share (TTM)$-0.40
ROE (5Y Avg)-19.41%
Operating Margin (TTM)-10.86%
Cash Flow / Share (Annual)$-0.10
P/B Ratio9.30x
P/B Ratio (Quarterly)7.02x
Net Income / Employee (Annual)$-25,200
EV / Revenue (TTM)9.21x
Net Interest Coverage (TTM)-0.96x
ROA (TTM)-13.48%
EV / EBITDA (TTM)225.80x
EPS Incl Extra (Annual)$-0.34
Current Ratio (Annual)5.11x
Quick Ratio (Quarterly)5.07x
3-Month Avg Trading Volume0.99M
52-Week Price Return296.30%
EV / Free Cash Flow (Annual)152711.73x
Revenue / Employee (TTM)$382,800
Tangible BV / Share (Quarterly)$4.47
P/S Ratio (Annual)10.11x
Asset Turnover (Annual)1.02x
52-Week High$45.83
Operating Margin (5Y Avg)-12.02%
EPS Excl Extra (Annual)$-0.34
CapEx CAGR (5Y)-24.37%
Tangible BV CAGR (5Y)0.16%
26-Week Price Return49.39%
Quick Ratio (Annual)3.04x
13-Week Price Return46.78%
Total Debt / Equity (Annual)0.38x
Current Ratio (Quarterly)7.10x
Enterprise Value$2.19B
Revenue / Share Growth (5Y)11.74%
Asset Turnover (TTM)1.02x
Book Value / Share Growth (5Y)-2.09%
Revenue / Employee (Annual)$362,100
Inventory Turnover (Annual)1.53x
Pretax Margin (Annual)-6.97%
Cash / Share (Annual)$0.88
3-Month Return Std Dev50.53%
Gross Margin (5Y Avg)77.74%
Net Income / Employee (TTM)$-50,600
ROE (Last FY)-12.19%
Net Interest Coverage (Annual)-0.96x
EPS Basic Excl Extra (Annual)$-0.34
P/FCF (TTM)251.27x
Receivables Turnover (TTM)8.72x
EV / Free Cash Flow (TTM)286.38x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.64
Receivables Turnover (Annual)8.96x
ROI (TTM)-16.74%
P/S Ratio (TTM)9.56x
Pretax Margin (5Y Avg)-13.60%
Revenue / Share (Annual)$4.89
Tangible BV / Share (Annual)$2.59
Forward P/E64.98x
Price vs S&P 500 (52W)271.93%
Year-to-Date Return30.77%
5-Day Price Return10.54%
EPS Normalized (Annual)$-0.34
ROA (5Y Avg)-10.15%
Net Profit Margin (Annual)-6.97%
Month-to-Date Return8.41%
Cash Flow / Share (TTM)$-0.46
EBITD / Share (Annual)$-0.03
Operating Margin (Annual)-3.49%
LT Debt / Equity (Annual)0.38x
P/CF (TTM)146.31x
ROI (5Y Avg)-13.51%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.64
P/TBV (Quarterly)7.24x
P/B Ratio (Annual)11.72x
Inventory Turnover (TTM)1.46x
Pretax Margin (TTM)-13.21%
Book Value / Share (Annual)$2.73
Price vs S&P 500 (13W)38.52%
Beta1.11x
P/FCF (Annual)206910.09x
Revenue / Share (TTM)$4.62
ROE (TTM)-20.74%
52-Week Low$9.22
vGradeF
gGradeB
mGradeA
vgmGradeB
Show chart for
Earnings Surprise History
Q1 260.07est. 0.07
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.18
4.19
4.19
4.19
Industry Peers — Electromedical Equipment(31)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
AXGNAxogen, Inc. Common Stock | F | B | A | $42.80 |
| MDTMedtronic plc | B | C | C | $81.67 |
| MASIMasimo Corporation | D | D | B | $178.82 |
| LIVNLivaNova PLC Ordinary Shares | C | C | B | $72.36 |
| ITGRInteger Holdings Corporation | B | C | C | $91.98 |
| TMDXTransMedics Group, Inc. Common Stock | C | B | D | $69.43 |
| BLFSBioLife Solutions Inc. | F | B | B | $26.65 |
| CNMDCONMED Corporation | A | C | D | $35.16 |
| INMDInMode Ltd. Ordinary Shares | A | D | C | $13.54 |
| CBLLCeriBell, Inc. Common Stock | D | A | B | $18.25 |
| CVCapsoVision, Inc. Common Stock | F | D | A | $7.19 |
About
Axogen commercializes regenerative medicine solutions for peripheral nerve repair, including grafts, connectors, and protective devices sold in the US, Canada, Europe, and select international markets. The company serves orthopedic and trauma surgeons with clinically validated products designed to improve surgical outcomes. Its portfolio includes Avance Nerve Graft, Axoguard connectors and protectors, and diagnostic assessment tools.